ACHV - Achieve Life Sciences, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.5900
+0.0598 (+3.91%)
As of 2:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.5302
Open1.5200
Bid1.5900 x 900
Ask1.6000 x 1000
Day's Range1.5200 - 1.6400
52 Week Range1.0400 - 4.6300
Volume15,976
Avg. Volume113,223
Market Cap12.875M
Beta (3Y Monthly)1.56
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACHV: Post Phase II Investor Day
    Zacks Small Cap Research

    ACHV: Post Phase II Investor Day

    By John Vandermosten, CFA NASDAQ:ACHV Achieve Life Sciences, Inc. (NASDAQ:ACHV) held its first investor day following the read out of the ORCA-1 trial on September 20, 2019. The event was introduced by CFO John Bencich and included a roundtable discussion moderated by analysts Michael Higgins of Ladenburg Thalmann and Jason McCarthy of Maxim Group. The key opinion

  • What Kind Of Share Price Volatility Should You Expect For Achieve Life Sciences, Inc. (NASDAQ:ACHV)?
    Simply Wall St.

    What Kind Of Share Price Volatility Should You Expect For Achieve Life Sciences, Inc. (NASDAQ:ACHV)?

    Anyone researching Achieve Life Sciences, Inc. (NASDAQ:ACHV) might want to consider the historical volatility of the...

  • Zacks Small Cap Research

    ACHV: SRNT Presentation Next on Agenda

    Achieve Life Sciences, Inc. (ACHV) released its second quarter results for 2019 and filed the companion 10-Q on August 8, 2019. No revenues were reported for the development stage company and operational expenses totaled $3.7 million producing a net loss of ($0.50) per share. During the three month period, the company completed the ORCA-1 Phase IIb study, was granted a patent for a new formulation of cytisinicline and reported statistically significant improvement in quit rates for cytisinicline.

  • Did You Manage To Avoid Achieve Life Sciences's (NASDAQ:ACHV) Painful 55% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Achieve Life Sciences's (NASDAQ:ACHV) Painful 55% Share Price Drop?

    Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of...

  • Benzinga

    Achieve Life Sciences Says Mid-Stage Data For Smoking Cessation Drug Accepted For Presentation At Conference

    Shares of thinly traded, nano-cap biotech Achieve Life Sciences Inc (NASDAQ: ACHV ) traded sharply higher  Friday morning before paring those gains. Achieve, which develops Cytisinicline – a plant-based ...

  • Zacks Small Cap Research

    ACHV: ORCA-1 Topline Results and Comparison

    Achieve Life Sciences, Inc. (ACHV) reported topline results from its Phase IIb Ongoing Research of Cytisinicline for Addiction (ORCA)-1 trial which was launched in October 2018. The study enrolled 254 subjects, employing six arms: four with active drug and two with placebo. The primary endpoint for the ORCA-1 study was the self-reported reduction in daily smoking.

  • Zacks Small Cap Research

    ACHV: 1Q:19 Financial & Operational Update

    Achieve Life Sciences, Inc. (ACHV) released its first quarter results for 2019 and filed the companion 10-Q on May 15, 2019. Since our previous update two months ago, the company announced the end of the ORCA-1 trial which is expected to produce topline results mid-year.

  • Zacks Small Cap Research

    ACHV: Final Enrollee, Final Visit

    Achieve Life Sciences, Inc. (ACHV) announced that its final enrollee had completed their final visit in the Phase IIb ORCA-1 trial on Wednesday. As a reminder the ORCA-1 (Ongoing Research of Cytisinicline for Addiction) trial is evaluating the effectiveness of cytisinicline for smoking cessation. The trial was designed as a multicenter, double blind, placebo-controlled trial in adult smokers randomized in a 2:2:1 ratio at 1.5 mg, 3.0 mg and placebo.

  • Benzinga

    The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...

  • Zacks Small Cap Research

    ACHV: Fiscal Year 2018 Operational and Financial Results

    Achieve Life Sciences, Inc. (ACHV) released its financial results for 2018 and filed the companion 10-K for the year ending December 31, 2018 on March 14, 2019. An investor conference call was held following the release to discuss recent achievements and financial results. Since our initiation, the company initiated a maximum tolerated dose (MTD) trial to examine the feasibility of a higher dose as they move into a Phase III trial.

  • Zacks Small Cap Research

    ACHV: A Reason to Quit is a Reason to Buy

    Achieve Life Sciences, Inc. (ACHV) is developing cytisinicline, historically known as cytisine, for nicotine addiction. Achieve has licensed cytisinicline for development and commercialization in the United States and most other geographies around the world including parts of Europe, the Middle East, Africa and Asia. The drug formulation has been used by over 20 million smokers in Central and Eastern Europe for smoking cessation and also in over 2,000 subjects in previously conducted investigator-led Phase 3 clinical trials.

  • Could The Achieve Life Sciences, Inc. (NASDAQ:ACHV) Ownership Structure Tell Us Something Useful?
    Simply Wall St.

    Could The Achieve Life Sciences, Inc. (NASDAQ:ACHV) Ownership Structure Tell Us Something Useful?

    Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! The big shareholder groups in Achieve Life Sciences, Inc. (NASDAQ:ACHV)Read More...

  • 5 Top Rising P/E Stocks to Enjoy Solid Gains
    Zacks

    5 Top Rising P/E Stocks to Enjoy Solid Gains

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
    Zacks

    Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

    Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals

  • 5 Top-Ranked Rising P/E Stocks to Lure Investors
    Zacks

    5 Top-Ranked Rising P/E Stocks to Lure Investors

    Inside the top-ranked stocks that have been exhibiting rising P/E ratios.